Think of the Neurokinin-1 Antagonists as Equally Efficacious

January 2016

Rolapitant (Varubi) will compete with older neurokinin-1 antagonists to prevent chemotherapy-induced nausea and vomiting.

It will join oral aprepitant and IV fosaprepitant (Emend, etc) and the combo of netupitant and the 5-HT3 antagonist palonosetron (Akynzeo).

We know that highly emetogenic chemotherapy (cisplatin, etc) requires using a three-drug regimen of a neurokinin-1 (NK-1) antagonist... 5-HT3 antagonist (ondansetron, etc)...and dexamethasone.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Medication Errors Help Standardize Stock In Operating Rooms
Infection Prevention Verify Catheters are Removed in Your PostOperative Patients
Hypertension Don't "SPRINT" to a Systolic BP Goal of < 120
Naloxone Verify That Patients Will Benefit From Topical NSAIDs at Discharge
Hepatitis C Watch Closely for Drug Interactions with Hep C Meds
Cardiology Tell Patients Clopidogrel Doesn't Increase Mortality
Antibiotics Limit Quinolone Use Due to Side Effects
Neurology & Pain Verify That Patients Will Benefit From Topical NSAIDs at Discharge
Vaccines Don't Stop Statins in Patients Getting the Flu Vaccine
Asthma Give Single Dose Dexamethasone for Pediatric Asthma Exacerbations in the ED
Diabetes Use a 1:1 Ratio When Switching from Insulin Degludec to Glargine or Detemir
Hematology & Oncology Think of the Neurokinin-1 Antagonists as Equally Efficacious

Think of the Neurokinin-1 Antagonists as Equally Efficacious

Get unlimited access through an Enterprise license

Table of Contents